Sienna Biopharmaceuticals Inc
Sienna Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of drugs in various therapeutic areas. It develops therapies in immunology and inflammation that target select pathways in tissues, such as skin. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical … Read more
Sienna Biopharmaceuticals Inc (SNNAQ) - Total Liabilities
Latest total liabilities as of September 2019: $20.39 Million USD
Based on the latest financial reports, Sienna Biopharmaceuticals Inc (SNNAQ) has total liabilities worth $20.39 Million USD as of September 2019.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Sienna Biopharmaceuticals Inc - Total Liabilities Trend (2015–2018)
This chart illustrates how Sienna Biopharmaceuticals Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Sienna Biopharmaceuticals Inc Competitors by Total Liabilities
The table below lists competitors of Sienna Biopharmaceuticals Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Pebble Beach Systems Group PLC
LSE:PEB
|
UK | GBX10.31 Million |
|
3P Land Holdings Limited
NSE:3PLAND
|
India | ₹196.91 Million |
|
Ba Ria Thermal Power JSC
VN:BTP
|
Vietnam | ₫147.46 Billion |
|
Fluoropharma Medical
PINK:FPMI
|
USA | $10.51 Million |
Liability Composition Analysis (2015–2018)
This chart breaks down Sienna Biopharmaceuticals Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 15.27 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.88 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.47 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Sienna Biopharmaceuticals Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Sienna Biopharmaceuticals Inc (2015–2018)
The table below shows the annual total liabilities of Sienna Biopharmaceuticals Inc from 2015 to 2018.
| Year | Total Liabilities | Change |
|---|---|---|
| 2018-12-31 | $80.72 Million | +76.84% |
| 2017-12-31 | $45.65 Million | +13.38% |
| 2016-12-31 | $40.26 Million | +2264.06% |
| 2015-12-31 | $1.70 Million | -- |